Resonium

Quick links to important sections

Resonium

Selected form

Treatment option: Anuria, Peritoneal Dialysis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Resonium

Property Description
Active Ingredient Sodium Polystyrene Sulfonate (SPS)
Form Powder for Suspension (Oral or Rectal)
Pharmacological Class Cation-Exchange Resin / Potassium Binder
General Purpose Management of high blood potassium levels
Origin Synthetic Polymer

Resonium: Definition and Pharmacological Class

Resonium is a trade name for the prescription medicinal entity Sodium Polystyrene Sulfonate (SPS), which is chemically a synthetic polymer resin designed to remain non-absorbed by the body. The active substance is classified pharmacologically as a Cation-Exchange Resin and functionally known as a Potassium Binder. This classification signifies that the medicine’s function is strictly chemical and physical, relying on an exchange principle rather than systemic absorption and metabolism. The pharmacological action is supported by data characterizing its role as a Cation-Exchange Resin.

Composition, Origin, and Available Forms

The medication is a single-ingredient product composed solely of the active substance, Sodium Polystyrene Sulfonate, which has a manufactured, synthetic origin. Unlike many solid oral dose forms, this product is typically supplied as a fine powder for suspension, a format clinically recognized for its versatility in administration. This powder form is essential because it allows the drug to be prepared into either an Oral Suspension for ingestion or a Rectal Suspension (retention enema), ensuring the resin can be delivered to the gastrointestinal tract via dual routes of administration.

The Core Function of a Cation-Exchange Resin

The general purpose of this product is rooted in its ability to function as an ion-exchange agent to help manage specific electrolyte levels. Within the intestines, the resin chemically traps excess potassium ions by exchanging them for its own sodium content, a process termed ion-exchange activity. Since the resin is an insoluble polymer, the entire potassium-bound material is subsequently excreted through the feces, preventing potassium absorption and thereby facilitating the reduction and management of high potassium levels in the body.

Regulatory References

  1. Sodium Polystyrene Sulfonate (SPS)
  2. MedlinePlus Drug Information
  3. Sodium Polystyrene Sulfonate
  4. high potassium levels
  5. ion-exchange activity
  6. NIH StatPearls

What side effects are possible with Resonium?

Possible side effects and safety information

The regulatory safety profile for Sodium Polystyrene Sulfonate (Resonium) is characterized by adverse reactions classified primarily within the Gastrointestinal Disorders and Metabolism and Nutrition Disorders system-organ classes, as documented in official government sources.

Adverse Reaction Classification

Side effects are categorized based on their official regulatory frequency:

  • Common/Frequent: Adverse reactions documented as common include Constipation, Nausea, Vomiting, Gastric irritation, and Anorexia (loss of appetite). Expected consequences of the drug's mechanism also classified as common are Hypokalemia (potassium depletion), Hypocalcemia, Hypomagnesemia, and significant sodium retention.
  • Rare/Post-marketing: Rare but serious events include Intestinal Necrosis, Intestinal Perforation, Ischemic Colitis, Gastrointestinal Ulceration, and Seizures.

Serious Adverse Reactions and Safety Constraints

The most serious adverse reactions listed in regulatory warnings are those related to the gastrointestinal tract, including Intestinal Necrosis (which may be fatal) and Intestinal Perforation.

Specific safety limitations are documented for administration:

  • Contraindications include pre-existing Hypokalemia and Obstructive Bowel Disease.
  • Use with Sorbitol is explicitly not recommended due to an increased risk of intestinal necrosis.
  • The medication is a sodium-containing product, necessitating caution in patients with sodium-sensitive conditions, such as severe hypertension or marked edema.

Population-Specific Safety Considerations

Official labeling includes explicit restrictions for vulnerable groups:

  • Neonates: Oral administration is strictly contraindicated due to the severe risk of intestinal obstruction. Rectal administration must be monitored closely to prevent complications like fecal impaction.
  • Children: There is an increased documented risk of fecal impaction with rectal administration.

This structure reflects the mandated communication of risks associated with the drug's non-absorbed, ion-exchange activity.

Overdose and Emergency Response

Overdosage with Sodium Polystyrene Sulfonate (Resonium) is officially documented to result in severe electrolyte disturbances, notably hypokalemia, hypocalcemia, and hypomagnesemia. The consequences of this electrolyte imbalance constitute the core overdose presentation.

Clinical manifestations resulting from the documented hypokalemia may include irritability, confusion, muscle weakness, and hyporeflexia, which may escalate to tetany. More critical outcomes listed in regulatory documents involve the potential for frank paralysis, apnea (cessation of breathing), and serious cardiac arrhythmias, characterized by a fast, slow, or irregular heartbeat. The official prescribing information states that no specific antidote is known for this overdose scenario.

When to Seek Immediate Medical Help

Regulatory authorities mandate that individuals must seek immediate medical attention for any suspected overdose exposure. Urgent contact with emergency services is required if the affected person exhibits life-threatening symptoms such as collapse, seizure, trouble breathing, or unconsciousness. Overdose management requires frequent serum potassium determinations and appropriate corrective measures to address the documented serum electrolyte imbalance, which may include physical removal of the resin from the alimentary tract. Specific care notes exist for neonates and low birth weight infants due to the risk of digestive hemorrhage or colonic necrosis.

Therapeutic Uses of Resonium

What Resonium Treats: Main Uses and Benefits

Resonium (Sodium Polystyrene Sulfonate) is commonly used to help with the management of high potassium levels in the blood, known as hyperkalemia, and the symptoms related to systemic imbalance. This medication is used specifically to help with this increased amount of potassium.

It is applicable within clinical settings that involve acute or disruptive symptom patterns, relevant in individuals with Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD). The core therapeutic focus contributes to easing the overall symptom burden and may also assist with managing symptoms of increased neurological or muscular activity such as muscle weakness and bothersome sensations like tingling.

This treatment is relevant in contexts involving heightened systemic burden, such as managing recurrent hyperkalemia between dialysis sessions. It helps maintain a sense of stability when symptoms are more noticeable during the periods between scheduled treatments. It is also applied in Acute Kidney Injury (AKI), where short-term symptomatic assistance is generally needed.


Quick Fact: Support for Hyperkalemia Management

The core purpose is to assist with managing potassium levels as part of a chronic management plan and supports the patient during difficult episodes by easing discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Resonium (Sodium Polystyrene Sulfonate) eligibility is strictly defined by regulatory authorities based on a patient's existing health status and age. The eligibility status is determined by official classifications, such as contraindications and conditional use warnings.


Contraindicated Populations

Use is absolutely prohibited for patients diagnosed with hypokalemia (low potassium levels) or obstructive bowel disease. It is also contraindicated for individuals with a known hypersensitivity to polystyrene sulfonate resins. Oral administration is contraindicated in neonates (newborns), and use must be avoided in patients who have not had a bowel movement post-surgery.


Conditional Use and Restrictions

The medicine requires caution for populations sensitive to an increased sodium load, such as patients with severe congestive heart failure or severe hypertension. Caution is also advised for patients at high risk of developing fecal impaction or constipation, and those with an impaired gag reflex (due to aspiration risk).


Age and Life Stage Eligibility

Beyond the prohibition of oral use in neonates, the effectiveness of Resonium has not been established in pediatric patients. For pregnancy and lactation, use is not expected to result in risk to the fetus or infant, as the drug is not absorbed systemically by the body.

What should I know about interactions with other medicines?

Interactions with Resonium (Sodium Polystyrene Sulfonate) are based on physical and chemical processes localized within the gastrointestinal tract, as the active substance is non-absorbed into the body.

The co-administration of Resonium with certain substances is strictly advised against. Combining Resonium with Sorbitol is officially restricted due to the documented risk of severe gastrointestinal injury, including intestinal necrosis.

Interactions Affecting Drug Absorption

Due to the resin's capacity to physically bind to other substances, taking Resonium concurrently with any other orally administered medicine can lead to a significant decrease in the absorption and reduced systemic exposure of the co-administered drug. To avoid this effect, official regulatory requirements mandate a precise timing separation: all other oral medicines must be taken at least three hours before or three hours after a dose of Resonium. For individuals with conditions that slow the movement of the digestive tract, such as delayed gastric emptying, this required time separation must be increased to six hours.

Pharmacodynamic and Cation Interactions

Caution is advised when using Resonium with cation-containing antacids or laxatives (such as those containing magnesium or calcium). This combination can interfere with the potassium-exchange capacity of Resonium and may increase the risk of developing systemic electrolyte imbalances. Additionally, Resonium may specifically reduce the absorption of oral Lithium and Thyroxine.

Mechanism of Action

Cation-Exchange Resin Mechanism

Resonium (Sodium/Calcium Polystyrene Sulfonate) is a non-absorbed, insoluble polymer designed as a cation-exchange resin. This mechanistic domain involves the drug remaining entirely within the gastrointestinal (GI) tract lumen, functioning as a cation-exchange polymer that exchanges its sodium or calcium ions for other positively charged ions from the intestinal contents.


Enteric Electrolyte Sequestration

The drug's primary action involves modifying early molecular steps within the gut. As the resin passes through the digestive system, particularly the large intestine, it engages in an ion-exchange process. It releases its own bound cation (sodium or calcium) and, in return, tightly binds and sequesters free potassium ions (K^+) present in the intestinal lumen.


Luminal Potassium Removal and Excretion

This mechanistic cascade induces a shift in the enteric potassium concentration. The resin, now carrying the sequestered potassium ions, is not metabolized or absorbed into the bloodstream. This complex is instead excreted via the feces, initiating a sequence that limits the total amount of potassium available for absorption and facilitates the excretion of K^+ via the gut's excretory pathway.

Dosage and Administration Information

How to Use Resonium: Administration Guidelines

Resonium (Sodium Polystyrene Sulfonate, SPS) is a medication used in the management of high blood potassium levels. Its administration is defined by established protocols, emphasizing proper preparation, precise dosing, and scheduling.


Routes and Preparation

Resonium is administered via two primary routes:

  • Oral: As a suspension that must be mixed from the powder immediately before use. The powder should be suspended in a small amount of water or syrup (typically 3 to 4 mL fluid per gram of resin). Do not mix with fruit juices or other liquids rich in potassium.
  • Rectal: Administered as a retention enema (often 30 g to 50 g) suspended in a suitable aqueous vehicle. The enema must be retained for several hours and followed by colonic irrigation.

Standard Dosing and Frequency

The dosage of Resonium is determined by a physician based on the patient’s condition and regular serum electrolyte determinations.

Population Typical Starting Dose Range (Oral) Frequency (Oral)
Adults 15 g per dose (up to 60 g total daily) One to four times daily (q.d. to q.i.d.)
Pediatric (Acute) 1 g/kg body weight daily in divided doses Multiple times per day

The treatment is typically discontinued when serum potassium levels reach a target determined by the clinician.


Administration Conditions and Timing

Two critical instructions govern the proper intake of Resonium:

  • Timing with other oral medications: Resonium must be administered at least 3 hours before or 3 hours after taking any other oral medications. This separation is necessary to prevent the resin from interfering with the absorption of other drugs.
  • Neonatal restriction: The oral route is contraindicated in neonates; only the rectal route may be considered, using the minimum effective dose (0.5 g/kg to 1 g/kg).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Resonium

Evidence for Use in Chronic High Potassium (Hyperkalemia)

Resonium (Sodium Polystyrene Sulfonate) has been studied in contexts exploring how high potassium levels were managed over time, particularly for individuals with Chronic Kidney Disease (CKD). The research base includes a limited number of smaller Randomized Controlled Trials (RCTs), alongside various Retrospective Observational Studies.

These studies were used in research exploring how potassium levels change over time. Researchers examined changes in Serum Potassium Levels as the main outcome, along with monitoring how many participants reached a specific, non-elevated potassium range. Findings describe patterns observed in these studied populations. The original regulatory approval of this product is also supported by its long history of medicinal use rather than relying solely on recent, large-scale clinical trials.

What remains uncertain is the availability of robust, large-scale RCTs specifically designed to evaluate long-term outcomes for this product. The data currently available for extended periods comes primarily from observational settings, and these types of studies are subject to recognized methodological limitations.

Research on Managing Acute High Potassium

Research examined Resonium's use in non-emergency scenarios where patients required short-term assistance with elevated potassium. The studies that explore this context are generally Retrospective Observational Studies involving hospitalized adult patients. The research explored short-term changes in potassium levels, usually monitored within the first 24 hours after administration.

Studies suggest that the time to observed effect was delayed and variable. Reported outcomes were short-term, limited to 24 hours post-dose. The research findings are limited to the observational settings in which they were conducted. A recognized factor is that the product has a delayed and variable onset of action.

Evidence Gaps and Research Uncertainty

A key limitation of the existing research structure is the modest sample sizes and limited follow-up durations found in some clinical trials. The reliance on older historical data for regulatory status means that comparative evidence using modern research protocols is lacking. Furthermore, due to the limited number of large-scale RCTs, long-term effects are not fully established, and evidence quality varies across studies. Research is ongoing in the broader field of potassium binders, and these findings highlight what is known and what is still uncertain about Resonium.

Key Studies & References Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study

Frequently Asked Questions (FAQ)

Common questions about Resonium (FAQ)


Q: Is Resonium the same as Kayexalate?

Resonium A is one trade name for the active drug, Sodium Polystyrene Sulfonate (SPS). Kayexalate is another well-known brand name for the same active ingredient, SPS. Official documents confirm that both products contain the same ion-exchange resin used to manage high potassium levels.


Q: Why would a doctor prescribe Resonium?

Official product information states that Resonium is prescribed to manage hyperkalemia, which refers to high levels of potassium in the blood. This condition is often associated with diseases like acute or chronic renal failure, or in cases of severe oliguria (low urine output).


Q: Does Resonium help with anything else besides potassium levels?

The drug’s main purpose is to bind and remove potassium. However, as an ion-exchange resin, it is not perfectly selective and may also bind small amounts of other positively charged ions, such as calcium and magnesium. Regulatory data classifies the resulting low levels of these electrolytes (hypocalcemia and hypomagnesemia) as common adverse reactions.


Q: Does Resonium interact with common heart medications?

Regulatory information indicates that Resonium can bind to any orally administered medication, including heart medicines like Digoxin, reducing their absorption and effectiveness. Additionally, if Resonium causes low potassium levels, the risk of heart toxicity from Digoxin can be heightened. This risk is documented in official labeling, which advises caution and close monitoring.


Q: How long does the effect of Resonium last?

Studies and official information indicate that the drug begins its action within 2 to 24 hours after administration. The drug’s direct effect, once started, may last for a limited time, typically up to 4 to 6 hours, as the resin is passed out of the body through the stool.


Q: Is Resonium used for short periods or long-term treatment?

The medication is approved for use in both acute (short-term) situations for severe potassium elevations and for the chronic (long-term) management of hyperkalemia. Official information states that the goal of treatment is to reach a target potassium range, at which point the medication is typically discontinued.


Q: What is the difference between Resonium A and Resonium Calcium?

Resonium A contains sodium polystyrene sulfonate, which exchanges sodium ions for potassium ions. Resonium Calcium contains calcium polystyrene sulfonate, exchanging calcium for potassium. The decision on which form to use is a clinical consideration based on the patient's specific electrolyte levels.


Q: Is it normal to have diarrhea when starting Resonium?

The official product information notes that common side effects include constipation, nausea, and vomiting. Diarrhea may occur, but regulatory data suggests it is typically categorized as an occasional or less frequent side effect compared to constipation.


Q: Can Resonium cause changes in other electrolyte levels?

Yes, official safety information indicates it can. While reducing potassium, the drug commonly causes low levels of other electrolytes. These adverse effects include hypomagnesemia (low magnesium) and hypocalcemia (low calcium).


Q: Does Resonium cause bloating or gas?

The official safety profile lists common gastrointestinal side effects such as gastric irritation, constipation, and stomach cramps. These effects, which are related to the resin passing through the digestive system, may contribute to a feeling of bloating or fullness.


Q: Are there any serious side effects I should watch out for with Resonium?

Yes, regulatory warnings highlight a risk of rare but serious gastrointestinal problems, including intestinal necrosis (severe gut damage) and perforation. Symptoms documented to require immediate attention include severe, constant abdominal or rectal pain, persistent nausea and vomiting, or black, bloody, or tarry stools.


Q: Can I mix Resonium with fruit juice?

Official administration instructions strictly advise against mixing Resonium with fruit juices. This is because many fruit juices contain high levels of potassium, which would directly counteract the drug’s intended effect of removing potassium from the body.


Q: Does Resonium have a strong taste?

The powder is designed to be taken as a suspension. According to product information, Resonium is generally described as having a sweet taste. Official product information notes that the powder is often flavored with additives like vanillin or saccharin.


Q: Can Resonium affect my sodium levels?

Yes. The sodium polystyrene sulfonate form releases sodium into the body, which can lead to significant sodium retention. Due to this potential sodium load, official documents advise that the medication be used with caution in patients with sodium-sensitive conditions, such as severe congestive heart failure or severe high blood pressure.


Q: What are the signs that Resonium is actually working?

The drug is not associated with perceptible signs that indicate it is working. The effectiveness of Resonium is determined only by regular clinical and biochemical control, specifically through monitoring serum potassium levels in the blood to ensure they are within the target range.


Q: Does the time of day I take Resonium matter?

The exact time of day for taking the medicine is not strictly mandated by the label. However, the timing relative to other oral medications is critical, as the drug must be taken at least 3 hours before or 3 hours after any other oral medicines.


Q: Is there a generic version of Resonium?

Yes. Resonium is a brand name. The drug's active ingredient, Sodium Polystyrene Sulfonate, is a commonly used compound and is available in numerous generic formulations listed by regulatory agencies.


Q: What happens when I stop taking Resonium?

Official warnings state that the drug should only be discontinued when potassium levels have reached the clinical target. Stopping the medication while hyperkalemia is still present carries a risk of potassium levels rising again and is not recommended without clinical guidance.

How should Resonium be stored and disposed of?

How to Store and Dispose of Resonium

The storage and disposal of Resonium (Sodium Polystyrene Sulfonate) are defined by strict regulatory requirements to ensure product stability and safety. The unmixed powder must be stored in a dry place at a temperature below 30 C and protected from direct heat and sunlight. The powder must never be heated, as this action can alter the resin's exchange properties.

For child safety, the medicine must be stored out of the reach and sight of children. The container should be kept tightly closed.

Crucially, the suspension prepared from the powder must be freshly made and not stored beyond 24 hours after reconstitution. Unused or expired product should be disposed of in accordance with local regulations, and the dry powder generally has no special disposal requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Resonium found in:

A-Z Index: